CL1-95012-001
22 Nov 2021
Trial Summary
A first in human Phase 1/2 open-label, multicenter, dose escalation and expansion study of PRS-344/S095012 in patients with solid tumors
Acronym:
CL1-95012-001
ACTRN/NCT /ethics:
NCT05159388
Scientific title:
A study of PRS-344/S095012 (PD-L1x4-1BB bispecific antibody) in patients with solid tumors
Sponsor / Cooperative group:
–
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | All stages |
| Anticipated Start Date | 2021-09-08 |
| Anticipated End Date | 2024-11-15 |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| Pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Dr Timothy Price |
| Recruitment Status | Recruiting |